Aldeyra Therapeutics, Inc. (ALDX) News
Follow Aldeyra Therapeutics, Inc. (ALDX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Aldeyra Therapeutics Reports Quarterly Results Through September 30
A machine-generated LSEG earnings summary covers the quarter ended September 30.
EQUITY | Nov 05, 2026, 11:25 PM UTC
L
Aldeyra Therapeutics 3Q 2026: EPS ($0.06) — 10-Q Summary
Aldeyra Therapeutics reported a narrower net loss in the third quarter as operating expenses declined, primarily reflecting lower external clinical development, personnel, manufacturing, preclinical and consulting costs.
EARNINGS | Nov 05, 2026, 09:17 PM UTC
L
HC Wainwright & Co. reiterates Neutral rating on Aldeyra Therapeutics, $2 price target
HC Wainwright & Co. reiterated their Neutral rating on Aldeyra Therapeutics's stock with a price target of $2.00.The price target implies an upside of 51.5% from the Sep 29 close of $1.32.Key takeaways from the analyst n
EQUITY | Sep 30, 2026, 10:24 AM UTC
L
Aldeyra Therapeutics Price Target Maintained With a $9.00/Share by BTIG
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 04:40 PM UTC
L
BTIG reiterates Buy rating on Aldeyra Therapeutics, $9 price target
BTIG reiterated their Buy rating on Aldeyra Therapeutics's stock with a price target of $9.00.The price target implies an upside of 675.9% from the Sep 28 close of $1.16.Key takeaways from the analyst notePositive Trial
EQUITY | Sep 29, 2026, 04:30 PM UTC
L
Aldeyra Intends to Submit FDA Formal Dispute Request for Reproxalap; Cash Runway Extended into 2029
Aldeyra intends to submit a Formal Dispute Resolution Request to the FDA appealing the March 16, 2026 Complete Response Letter for reproxalap and reports operational cash runway extended into 2029.Key Highlights:Original
REGULATION | Sep 29, 2026, 11:03 AM UTC
L
Aldeyra Therapeutics, Inc. (ALDX) To File FDA FDRR on Reproxalap; Cash Runway Into 2029
Aldeyra plans an FDA Formal Dispute Resolution Request for reproxalap after a March 16, 2026 CRL, with OND meeting expected in Q4 2026. The company also guided operational cash runway into 2029.Material DetailsContext by
REGULATION | Sep 29, 2026, 11:01 AM UTC
L
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced intent to submit to the U
REGULATION | Sep 29, 2026, 11:00 AM UTC
L
Aldeyra Therapeutics to Host Regulatory Update Webcast
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the company will hos
NEWS | Sep 28, 2026, 08:30 PM UTC
L
ALDX - Aldeyra Therapeutics To Request FDA Type D Meeting On NDA Of Reproxalap Resubmission By End Of Q3 2026 per SEC filing
ALDX - Aldeyra Therapeutics To Request FDA Type D Meeting On NDA Of Reproxalap Resubmission By End Of Q3 2026 per SEC filing
REGULATION | Jul 15, 2026, 09:09 PM UTC